Publication | Research group | Exp. | Figure | Reactivation session duration | MDZ dose (mg/kg) | Ntotal | Effect size (Hedges’ g) |
---|---|---|---|---|---|---|---|
Bustos et al. (2006) | I | 1B | 2B | 90 s | 1 | 16 | 1.93* |
Bustos et al. (2006) | I | 2A | 3B | 90 s | 1 | 17 | 2.40* |
Bustos et al. (2006) | I | 2A | 3B | 90 s | 1 | 17 | 2.34* |
Bustos et al. (2006) | I | 3B | 7B | 90 s | 1 | 16 | 4.60* |
Zhang and Cranney (2008) | II | 1 | 1 | 90 s | 2 | 18 | 0.96* |
Zhang and Cranney (2008) | II | 3 | 3 | 90 s | 2 | 16 | 1.76* |
Bustos et al. (2009) | I | NA | 1B | 1 min | 1.5 | 14 | 0.74 |
Bustos et al. (2009) | I | NA | 1C | 3 min | 1.5 | 14 | 3.63* |
Bustos et al. (2009) | I | NA | 1D | 5 min | 1.5 | 20 | 2.95* |
Bustos et al. (2009) | I | NA | 2C | 10 min | 1.5 | 15 | −2.06 |
Bustos et al. (2009) | I | NA | 3B | 3 min | 1.5 | 14 | 3.13* |
Bustos et al. (2010) | I | 1 | 1B | 3 min | 1.5 or 3 | 17 | 2.52* |
Bustos et al. (2010) | I | 1 | 1C | 5 min | 1.5 or 3 | 19 | 2.41* |
Stern et al. (2012) | III | 1 | 1A | 3 min | 1.5 | 20 | 1.31* |
Pineyro et al. (2013) | IV | 1 | 1C | 1 min | 3 | 12 | 0.04 |
Pineyro et al. (2013) | IV | 1 | 1C | 4 min | 3 | 12 | 3.53* |
Pineyro et al. (2013) | IV | 1 | 1C | 5 min | 3 | 12 | 2.96* |
Alfei et al. (2015) | IV | 5 | 5A | 2 min | 3 | 18 | 1.71* |
Alfei et al. (2015) | IV | 6 | 6B | 5 min | 3 | 14 | 2.59* |
Ortiz et al. (2015) | I | 1 | 1C | 3 min | 3 | 19 | 3.22* |
Ortiz et al. (2015) | I | 1 | 1E | 5 min | 3 | 12 | 4.11* |
Ortiz et al. (2015) | I | 2 | 3C | 5 min | 3 | 16 | 4.10* |
Ferrer Monti et al. (2016) | IV | 1 | 1C | 90 s | 3 | 15 | –0.05 |
Ferrer Monti et al. (2016) | IV | 1 | 1C | 4 min | 3 | 14 | 2.79* |
Espejo et al. (2016) | I | 1 | 1 | 5 min | 3 | 15 | 3.92* |
Espejo et al. (2016) | I | 2 | 2 | 5 min | 3 | 22 | 2.91* |
Saitoh et al. (2017) | V | NA | 2B | 3 min | 1 | 24 | 0.85* |
Ferrer Monti et al. (2017) | IV | 2 | 2B | 2 min | 3 | 12 | 3.58* |
Espejo et al. (2017) | I | 1 | 1 | 5 min | 3 | 16 | 3.30* |
Espejo et al. (2017) | I | 3 | 3 | 5 min | 3 | 18 | 3.73* |
Akagi et al. (2018) | V | NA | 2C | 3 min | 1 | 30 | 0.83* |
Franzen et al. (2019) | III | NA | 1A | 1 min | 3 | 18 | –0.12 |
Franzen et al. (2019) | III | NA | 1B | 2 min | 3 | 17 | 1.39* |
Adapted from Schroyens et al. (2019a). See Inclusion criteria for an overview of which conditions were included. Studies that used contextual fear conditioning and postreactivation systemic MDZ injection in rats were included after a thorough literature search. Note that two additional papers with MDZ studies were identified by our systematic PubMed search and included in the preregistered analyses (De Oliveira Alvares et al., 2013; Couto-Pereira et al., 2019). The effect size (Hedges’ g) for the influence of MDZ on % freezing during the test session was estimated based on means and SEs from reported graphs (MDZ vs vehicle) using the metafor package in R. Details of the intervention, such as duration of the training and reactivation session and drug dose, are indicated as well.
*Amnestic effects reported as significant (at an α level of 0.05). The numbers in the second column refer to the research group,
I, IFEC-CONICET, Departamento de Farmacología, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
II, School of Psychology, University of New South Wales, Sydney, Australia.
III, Department of Pharmacology, Federal University of Santa Catarina, Florianópolis, Santa Catarina, Brazil.
IV, Laboratorio de Psicología Experimental, Facultad de Psicología, Universidad Nacional de Córdoba, Córdoba, Argentina.
V, Department of Neuropsychopharmacology, National Institute of Mental Health, National left of Neurology and Psychiatry, Tokyo, Japan.